Alzheimer's blood marker may help estimate cognitive impairment risk up to 10 years ahead
Researchers say p-tau217 blood levels can translate into personalized five- and 10-year dementia risk estimates, but the test is not yet recommended for routine screening.
- Researchers published a study in JAMA detailing a new blood test for advanced Alzheimer disease, developed with Alamar Biosciences to track the extent of tau tangle accumulation in the brain.
- Existing blood tests identify early Alzheimer disease changes but lack information on advanced tangle buildup, which is more closely associated with cognitive impairment and disease severity.
- Investigators analyzed blood samples from 521 brain donors and 207 imaging participants, finding biomarker concentrations 25.2 to 50.5 times higher in advanced pathology; the test requires just 35 µL of plasma.
- The assay accurately distinguished participants with tau pathology, achieving performance comparable to mass spectrometry, said Nicholas Ashton, PhD, senior director of Banner Sun Health Research Institute's Fluid Biomarker Program.
- Although not yet available for clinical use, the test offers a scalable way to stage Alzheimer disease and select patients for Clinical Trials, helping doctors make better treatment decisions.
15 Articles
15 Articles
Alzheimer’s blood marker could predict cognitive decline risks, says Mayo Clinic - NEW YORK TIMES POST
NEWYou can now listen to Fox News articles! A blood test that detects a protein linked to Alzheimer’s disease could help predict whether older adults will develop cognitive decline within five to 10 years, according to a new Mayo Clinic study published in JAMA Neurology. The study looked at levels of phosphorylated tau 217 (p-tau217) [...]
A Mayo Clinic model uses p-tau217 blood levels, age, sex and genetics to estimate future cognitive impairment risk—but it is not a diagnosis or recommended for routine screening.
A Mayo Clinic study found that p-tau217 blood levels combined with age, sex and genetic risk can estimate five- and 10-year cognitive impairment risk, though the model is not diagnostic.
Researchers create new blood test to better measure advanced Alzheimer's disease
Washington: Researchers at Banner Health, Lund University in Sweden and other renowned international collaborators have demonstrated the first scalable blood test that measures a protein fragment called eMTBR-tau that tracks the buildup of tau tangles - a key sign of Alzheimer's disease.In a study published in Journal of the American Medical Association (JAMA), the newly developed blood test accurately detected advanced tau pathology and showed …
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium













